ArticleEuropean urology2018
Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
Article in European urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.Nature communications · 2025Pooled it
- Mendelian randomization study on the causal relationship between leukocyte telomere length and prostate cancer.PloS one · 2023Pooled it
- Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer.Bioscience reports · 2020Pooled it
- Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.Human molecular genetics · 2020Pooled it
- Transcriptome-wide association studies implicate RCC1 and PHACTR4 in prostate cancer survival.European journal of human genetics : EJHG · 2026Article
- Polygenic risk score and 20-year prostate cancer-specific mortality and survival.Communications medicine · 2026Article
- Article
- Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma.Acta pharmaceutica Sinica. B · 2026Article
- Analysing DNA methylation and transcriptomic signatures to predict prostate cancer recurrence risk.Discover oncology · 2025Article
- Cellular Signaling of Amino Acid Metabolism in Prostate Cancer.International journal of molecular sciences · 2025Review
- Potential Molecular Markers for Cholecystic Inflammation-Induced Carcinogenesis Based on RNA-Seq Gene Screening.Combinatorial chemistry & high throughput screening · 2025Article
- A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.Nature communications · 2024Article
- Predictive value of polygenic risk score for prostate cancer incidence and prognosis in the Han Chinese.Scientific reports · 2024Article
- Construction and evaluation of a polygenic hazard score for prognostic assessment in localized gastric cancer.Fundamental research · 2024Article
- Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.medRxiv : the preprint server for health sciences · 2024Article
- Causal relationship between Alzheimer's disease and prostate cancer: a bidirectional Mendelian randomization analysis.Frontiers in endocrinology · 2024Article
- Diabetes mellitus and prostate cancer risk: A mendelian randomization analysis.World journal of diabetes · 2023Article
- Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023Article
- Associations between genetic variants in sphingolipid metabolism pathway genes and hepatitis B virus-related hepatocellular carcinoma survival.Frontiers in oncology · 2023Article
- Emerging Materials, Wearables, and Diagnostic Advancements in Therapeutic Treatment of Brain Diseases.Biosensors · 2022Review
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
backgroundMost men diagnosed with prostate cancer have low-risk cancers. How to predict prostate cancer progression at the time of diagnosis remains challenging.
objectiveTo identify single nucleotide polymorphisms (SNPs) associated with death from prostate cancer. DESIGN, SETTING, AND
participantsBlood samples from 11 506 men in Sweden were collected during 1991-1996. Of these, 1053 men were diagnosed with prostate cancer and 245 died from the disease. Stage and grade at diagnosis and outcome information were obtained, and DNA from all cases was genotyped. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A total of 6 126 633 SNPs were tested for association with prostate-cancer-specific survival time using a Cox proportional hazard model, adjusted for age, stage, and grade at diagnosis. A value of 1×10 RESULTS AND LIMITATIONS: We found 12 SNPs at seven independent loci associated with prostate-cancer-specific survival time. One of 6 126 633 SNPs tested reached genome-wide significance (p<5×10
conclusionsThe SNP rs73055188 at the AOX1 locus is associated with prostate-cancer-specific survival time, and AOX1 gene expression level is correlated with biochemical recurrence of prostate cancer. PATIENT SUMMARY: We identify two genetic markers that are associated with prostate-cancer-specific survival time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.